Wnt4 inhibits cell motility induced by oncogenic Ras

Oncogene

Volumn 32, Issue 35, 2013, Pages 4110-4119

  De Menna, M ^a   D'Amato, V ^a   Ferraro, A ^a   Fusco, A ^a,b   Di Lauro, R ^a   Garbi, C ^a   De Vita, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

Author keywords

cancer; cell motility; miR 24; Ras; Wnt4

Indexed keywords

ACTIN; MICRORNA; MICRORNA 24; RAS PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; WNT4 PROTEIN;

3' UNTRANSLATED REGION; ACTIN FILAMENT; ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL MIGRATION; CELL MOTILITY; CELL TRANSFORMATION; CONTROLLED STUDY; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID CARCINOMA;

ANIMALS; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; CYTOSKELETON; GENES, RAS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; RATS; THYROID GLAND; THYROID NEOPLASMS; WNT4 PROTEIN;

EID: 84883490045     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.419     Document Type: Article

References (38)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006; 6: 292-306.
3. Malumbres M, Barbacid MRAS. oncogenes: the first 30 years. Nat Rev Cancer 2003; 3: 459-465.
4. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295-308.
5. Hingorani SR, Tuveson DA. Ras redux: rethinking how and where Ras acts. Curr Opin Genet Dev 2003; 13: 6-13.
6. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995; 80: 179-185.
7. Cully MYH, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6: 184-192.
8. Engelman JALJ, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006; 7: 606-619.
9. Braga VM, Betson M, Li X, Lamarche-Vane N. Activation of the small GTPase Rac is sufficient to disrupt cadherin-dependent cell-cell adhesion in normal human keratinocytes. Mol Biol Cell 2000; 11: 3703-3721.
10. Quinlan MP. Rac regulates the stability of the adherens junction and its components, thus affecting epithelial cell differentiation and transformation. Oncogene 1999; 18: 6434-6442.
11. Arthur WT, Burridge K. RhoA inactivation by p190RhoGAP regulates cell spreading and migration by promoting membrane protrusion and polarity. Mol Biol Cell 2001; 12: 2711-2720.
12. Parri M, Chiarugi P. Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal 2010; 8: 23.
13. De Vita G, Bauer L, da Costa VM, De Felice M, Baratta MG, De Menna M et al. Dose-dependent inhibition of thyroid differentiation by RAS oncogenes. Mol Endocrinol 2005; 19: 76-89.
14. Frezzetti D, De Menna M, Zoppoli P, Guerra C, Ferraro A, Bello AM et al. Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene 2011; 30: 275-286.
15. Stark K, Vainio S, Vassileva G, McMahon AP. Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by Wnt-4. Nature 1994; 372: 679-683.
16. Vainio S, Heikkila M, Kispert A, Chin N, McMahon AP. Female development in mammals is regulated by Wnt-4 signalling. Nature 1999; 397: 405-409.
17. Vainio SJ. Nephrogenesis regulated by Wnt signaling. J Nephrol 2003; 16: 279-285.
18. Tanigawa S, Wang H, Yang Y, Sharma N, Tarasova N, Ajima R et al. Wnt4 induces nephronic tubules in metanephric mesenchyme by a non-canonical mechanism. Dev Biol 2011; 352: 58-69.
19. Vincent JP, Beckett K. Off-track takes Frizzled off the canonical path. EMBO J 2011; 30: 3665-3666.
20. Schlessinger K, Hall A, Tolwinski N. Wnt signaling pathways meet Rho GTPases. Genes Dev 2009; 23: 265-277.
21. Taki M, Kamata N, Yokoyama K, Fujimoto R, Tsutsumi S, Nagayama M. Downregulation of Wnt-4 and up-regulation of Wnt-5a expression by epithelialmesenchymal transition in human squamous carcinoma cells. Cancer Sci 2003; 94: 593-597.
22. Bui TD, Zhang L, Rees MC, Bicknell R, Harris AL. Expression and hormone regulation of Wnt2, 3, 4, 5a, 7a, 7b and 10b in normal human endometrium and endometrial carcinoma. Br J Cancer 1997; 75: 1131-1136.
23. Huguet EL, McMahon JA, McMahon AP, Bicknell R, Harris AL. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res 1994; 54: 2615-2621.
24. Benhaj K, Akcali KC, Ozturk M. Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncol Rep 2006; 15: 701-707.
25. Miyakoshi T, Takei M, Kajiya H, Egashira N, Takekoshi S, Teramoto A et al. Expression of Wnt4 in human pituitary adenomas regulates activation of the betacatenin-independent pathway. Endocr Pathol 2008; 19: 261-273.
26. Kimura T, Van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocrine Reviews 2001; 22: 631-656.
27. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007; 129: 1401-1414.
28. Baratta MGPI, Di Lauro R. Oncogenic ras blocks the cAMP pathway and dedifferentiates thyroid cells via animpairment of pax8 transcriptional activity. Mol Endocrinol 2009; 23: 838-848.
29. Jeays-Ward K, Hoyle C, Brennan J, Dandonneau M, Alldus G, Capel B et al. Endothelial and steroidogenic cell migration are regulated by WNT4 in the developing mammalian gonad. Development 2003; 130: 3663-3670.
30. Roger PP, van Staveren WC, Coulonval K, Dumont JE, Maenhaut C. Signal transduction in the human thyrocyte and its perversion in thyroid tumors. Molecular and Cellular Endocrinology 2010; 321: 3-19.
31. Drosten M, Dhawahir A, Sum EY, Urosevic J, Lechuga CG, Esteban LM et al. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. Embo J 2011; 29: 1091-1104.
32. Herrera Abreu MTHW, Mele K, Lyons RJ, Rickwood D, Browne BC, Bennett HL et al. Gab2 regulates cytoskeletal organization and migration of mammary epithelial cells by modulating RhoA activation. Mol Biol Cell 2011; 22: 105-116.
33. Bhushan L, Kandpal RP. EphB6 receptor modulates micro RNA profile of breast carcinoma cells. PLoS One 2011; 6: e22484.
34. Qin WSY, Zhao B, Yao C, Jin L, Ma J, Jin Y. miR-24 regulates apoptosis by targeting the open reading frame (orf) region of FAF1 in cancer cells. PLoS ONE 2010; 5: e9429.
35. Xie LWT, Yu S, Chen X, Wang L, Qian X, Yu L et al. Cell-free miR-24 and miR-30d, potential diagnostic biomarkers in malignant effusions. Clin Biochem 2011; 44: 216-220.
36. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261.
37. Hatziapostolou MPC, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, Ogata H et al. An HNF4alpha-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 2011; 147: 1233-1247.
38. Papadimitriou EVE, Vorvis C, Iliopoulos D, Moustakas A, Kardassis D, Stournaras C. Differential regulation of the two RhoA-specific GEF isoforms Net1/Net1A by TGF-beta and miR-24: role in epithelial-to-mesenchymal transition. Oncogene 2012; 31: 2862-2875.